Vertebral Fractures in Boys with Duchenne Muscular Dystrophy

Overview

Journal Clin Pediatr (Phila)

Publisher Sage Publications

Specialty Pediatrics

Date 2003 Jun 13

PMID 12800730

Citations 25

Authors

J E Bothwell

K E Gordon

J M Dooley

J MacSween

E A Cummings

S Salisbury

Affiliations

Soon will be listed here.

Abstract

Osteoporosis causes significant morbidity for boys with Duchenne muscular dystrophy. Corticosteroid therapy given to prolong mobility may increase the rate of osteoporosis and risk of fracture. This study of 33 boys with Duchenne muscular dystrophy determined retrospectively the incidence of vertebral fractures particularly after initiation of corticosteroids. A latency period of 40 months after commencement of steroids occurred before the first vertebral fracture appeared. However, by 100 months of treatment approximately 75% had sustained a vertebral fracture.

Citing Articles

Approach to the Pediatric Patient With Glucocorticoid-Induced Osteoporosis.

Ward L, Bakhamis S, Bakhamis S, Koujok K J Clin Endocrinol Metab. 2024; 110(2):572-591.

PMID: 39126675 PMC: 11747689. DOI: 10.1210/clinem/dgae507.

Is endocrine surveillance important in the care of Duchenne Muscular Dystrophy? Results from a national survey to patients and families on endocrine complications.

Galetaki D, Szymczuk V, Shi M, Merchant N eNeurologicalSci. 2024; 36:100513.

PMID: 38989274 PMC: 11231648. DOI: 10.1016/j.ensci.2024.100513.

Bisphosphonates in Glucocorticoid-Treated Patients With Duchenne Muscular Dystrophy: A Systematic Review and Grading of the Evidence.

Landfeldt E, Phung K, Zaman F, Astrom E, Abner S, Lochmuller H Neurology. 2024; 102(2):e207948.

PMID: 38165327 PMC: 10962906. DOI: 10.1212/WNL.0000000000207948.

Moving Beyond the 2018 Minimum International Care Considerations for Osteoporosis Management in Duchenne Muscular Dystrophy (DMD): Meeting Report from the 3rd International Muscle-Bone Interactions Meeting 7th and 14th November 2022.

Phung K, Crabtree N, Connolly A, Furlong P, Hoffman E, Jackowski S J Neuromuscul Dis. 2023; 11(1):233-252.

PMID: 37980681 PMC: 10789336. DOI: 10.3233/JND-230176.

Partial Ablation of Non-Myogenic Progenitor Cells as a Therapeutic Approach to Duchenne Muscular Dystrophy.

Gao Z, Lu A, Daquinag A, Yu Y, Huard M, Tseng C Biomolecules. 2021; 11(10).

PMID: 34680151 PMC: 8534118. DOI: 10.3390/biom11101519.